Olivier Capitain

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

John Crown, Véronique Dièras, Elżbieta Starosławska et al. · Journal of Clinical Oncology · 2013 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway

Laurence Gamelin, Olivier Capitain, Alain Morel et al. · Clinical Cancer Research · 2007 · 123 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial

F. Legouté, René‐Jean Bensadoun, Valérie Seegers et al. · Radiation Oncology · 2019 · 110 citations · Full text

Medicine, Oncology, Radiation Oncology +17